Celgene diversifies with $7.2bn Receptos buy

Celgene believes that its all cash $7.2bn acquisition of Receptos will add at least $4bn to $6bn in peak annual sales to the company's future revenue and help the biotechnology giant exceed a previous goal of $20bn in annual revenue.